Patrice Cacoub1, François Dabis, Dominique Costagliola, Kayigan Almeida, France Lert, Lionel Piroth, Caroline Semaille. 1. Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UMR 7211, UPMC Univ Paris 06, Paris, F-75005, France; INSERM, UMR_S 959, Paris, F-75013, France; CNRS, FRE3632, Paris, F-75005, France; Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, F-75013, France.
Abstract
BACKGROUND & AIMS: To better evaluate the HIV-HCV co-infection burden in the context of new effective HCV treatment. METHODS: We reviewed all the epidemiological data available on HCV-related disease in HIV-infected patients in France. Sources of data have been selected using the following criteria: (i) prospective cohorts or cross-sectional surveys; (ii) conducted at a national level; (iii) in the HIV-infected population; (iv) able to identify HCV co-infection and chronic active hepatitis C (HCV RNA positive); and (v) conducted during the period 2003-2012. RESULTS: The overall prevalence of HIV-HCV co-infection has decreased from 22-24% to 16-18%. This prevalence decreased from 93% to 87% among injecting drug users while it increased from 4% to 6% among men who have sex with men. The characteristics of patients have changed: decrease in the proportion of patients with chronic active hepatitis C (HCV RNA positive) from 77% to 63% and in the genotypes 2 and 3 HCV infection; increase in the proportion of HCV genotype 1 (from 45-50% to 58%) and genotype 4 (from 15% to 22%). The proportion of patients treated with highly active antiretroviral therapy increased from 76% to 95%, with higher rates of undetectable HIV viral load (47% in 2004 vs. 85% in 2012). CONCLUSION: The decreasing prevalence and the change in patients profile in HIV-HCV co-infection underline the importance of continuing efforts to educate physicians and patients. This should increase the benefit of viral risk reduction policies and increase the access of co-infected patients to HCV treatment.
BACKGROUND & AIMS: To better evaluate the HIV-HCV co-infection burden in the context of new effective HCV treatment. METHODS: We reviewed all the epidemiological data available on HCV-related disease in HIV-infectedpatients in France. Sources of data have been selected using the following criteria: (i) prospective cohorts or cross-sectional surveys; (ii) conducted at a national level; (iii) in the HIV-infected population; (iv) able to identify HCV co-infection and chronic active hepatitis C (HCV RNA positive); and (v) conducted during the period 2003-2012. RESULTS: The overall prevalence of HIV-HCV co-infection has decreased from 22-24% to 16-18%. This prevalence decreased from 93% to 87% among injecting drug users while it increased from 4% to 6% among men who have sex with men. The characteristics of patients have changed: decrease in the proportion of patients with chronic active hepatitis C (HCV RNA positive) from 77% to 63% and in the genotypes 2 and 3 HCV infection; increase in the proportion of HCV genotype 1 (from 45-50% to 58%) and genotype 4 (from 15% to 22%). The proportion of patients treated with highly active antiretroviral therapy increased from 76% to 95%, with higher rates of undetectable HIV viral load (47% in 2004 vs. 85% in 2012). CONCLUSION: The decreasing prevalence and the change in patients profile in HIV-HCV co-infection underline the importance of continuing efforts to educate physicians and patients. This should increase the benefit of viral risk reduction policies and increase the access of co-infected patients to HCV treatment.
Authors: Mattias Mandorfer; Philipp Schwabl; Sebastian Steiner; Thomas Reiberger; Markus Peck-Radosavljevic Journal: Hepatol Int Date: 2016-01-12 Impact factor: 6.047
Authors: Edward R Cachay; David Wyles; Lucas Hill; Craig Ballard; Francesca Torriani; Bradford Colwell; Alexander Kuo; Robert Schooley; Christopher W Mathews Journal: Open Forum Infect Dis Date: 2015-11-12 Impact factor: 3.835
Authors: Bernhard Scheiner; Philipp Schwabl; Sebastian Steiner; Theresa Bucsics; David Chromy; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger; Mattias Mandorfer Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889
Authors: Karine Lacombe; Hélène Fontaine; Catherine Dhiver; Sophie Metivier; Eric Rosenthal; Teresa Antonini; Marc Antoine Valantin; Patrick Miailhes; Stanislas Harent; Dominique Batisse; Georges-Philippe Pageaux; Julie Chas; Hugues Aumaitre; Stephanie Dominguez; Thierry Allegre; Alain Lafeuillade; Eric Billaud; Pierre De Truchis; Philippe Perre; Vincent Leroy; Victor De Ledinghen; Philippe Sogni; François Dabis; Yue Zhao; Anne Filipovics; Larysa Fedchuk; Raoudha Akremi; Yacia Bennai; Dominique Salmon Ceron Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731